Chinese investor group backs BioAtla in $30M round

BioAtla LLC (San Diego, Calif.) raised $30 million in equity funding from an undisclosed investor group based in China.

The company is developing early stage Conditionally Active Biologics (CABs) that are activated in select microenvironments. BioAtla said the CAB technology can be applied to mAbs, bispecific antibodies, antibody drug conjugates, immune checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. ...